229 related articles for article (PubMed ID: 16393888)
1. Metabolism and transport of oxazaphosphorines and the clinical implications.
Zhang J; Tian Q; Yung Chan S; Chuen Li S; Zhou S; Duan W; Zhu YZ
Drug Metab Rev; 2005; 37(4):611-703. PubMed ID: 16393888
[TBL] [Abstract][Full Text] [Related]
2. Design of new oxazaphosphorine anticancer drugs.
Liang J; Huang M; Duan W; Yu XQ; Zhou S
Curr Pharm Des; 2007; 13(9):963-78. PubMed ID: 17430192
[TBL] [Abstract][Full Text] [Related]
3. Oxazaphosphorines combined with immune checkpoint blockers: dose-dependent tuning between immune and cytotoxic effects.
Delahousse J; Skarbek C; Desbois M; Perfettini JL; Chaput N; Paci A
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32784216
[TBL] [Abstract][Full Text] [Related]
4. Insights into oxazaphosphorine resistance and possible approaches to its circumvention.
Zhang J; Tian Q; Chan SY; Duan W; Zhou S
Drug Resist Updat; 2005 Oct; 8(5):271-97. PubMed ID: 16154799
[TBL] [Abstract][Full Text] [Related]
5. Preactivated oxazaphosphorines designed for isophosphoramide mustard delivery as bulk form or nanoassemblies: synthesis and proof of concept.
Skarbek C; Lesueur LL; Chapuis H; Deroussent A; Pioche Durieu C; Daville A; Caron J; Rivard M; Martens T; Bertrand JR; Le Cam E; Vassal G; Couvreur P; Desmaele D; Paci A
J Med Chem; 2015 Jan; 58(2):705-17. PubMed ID: 25494842
[TBL] [Abstract][Full Text] [Related]
6. [Classical oxazaphosphorines--metabolism and therapeutic properties--new implications].
Sloderbach A; Górska A; Sikorska M; Misiura K; Hładoń B
Postepy Hig Med Dosw (Online); 2013 Dec; 67():1235-53. PubMed ID: 24379264
[TBL] [Abstract][Full Text] [Related]
7. Oxazaphosphorine bioactivation and detoxification The role of xenobiotic receptors.
Wang D; Wang H
Acta Pharm Sin B; 2012 Apr; 2(2):. PubMed ID: 24349963
[TBL] [Abstract][Full Text] [Related]
8. Reversal of resistance to oxazaphosphorines.
Zhang J; Tian Q; Zhu YZ; Xu AL; Zhou SF
Curr Cancer Drug Targets; 2006 Aug; 6(5):385-407. PubMed ID: 16918308
[TBL] [Abstract][Full Text] [Related]
9. Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics.
Chen CS; Lin JT; Goss KA; He YA; Halpert JR; Waxman DJ
Mol Pharmacol; 2004 May; 65(5):1278-85. PubMed ID: 15102956
[TBL] [Abstract][Full Text] [Related]
10. Thiazolidinyl- and perhydrothiazinylphosphamidesters: toxicity and preliminary antitumour evaluation.
Voelcker G; Bielicki L; Hohorst HJ
J Cancer Res Clin Oncol; 1997; 123(11-12):623-31. PubMed ID: 9620221
[TBL] [Abstract][Full Text] [Related]
11. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene.
Chen L; Waxman DJ; Chen D; Kufe DW
Cancer Res; 1996 Mar; 56(6):1331-40. PubMed ID: 8640822
[TBL] [Abstract][Full Text] [Related]
12. Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer.
Roy P; Waxman DJ
Toxicol In Vitro; 2006 Mar; 20(2):176-86. PubMed ID: 16293390
[TBL] [Abstract][Full Text] [Related]
13. In vitro cytotoxicity testing of new generation oxazaphosphorines against human histiocytic lymphoma cells.
Opydo-Chanek M; Mazur L; Stojak M
Indian J Exp Biol; 2013 Aug; 51(8):615-22. PubMed ID: 24228385
[TBL] [Abstract][Full Text] [Related]
14. Activation of the anticancer drugs cyclophosphamide and ifosfamide by cytochrome P450 BM3 mutants.
Vredenburg G; den Braver-Sewradj S; van Vugt-Lussenburg BM; Vermeulen NP; Commandeur JN; Vos JC
Toxicol Lett; 2015 Jan; 232(1):182-92. PubMed ID: 25448283
[TBL] [Abstract][Full Text] [Related]
15. Oxazaphosphorines: new therapeutic strategies for an old class of drugs.
Giraud B; Hebert G; Deroussent A; Veal GJ; Vassal G; Paci A
Expert Opin Drug Metab Toxicol; 2010 Aug; 6(8):919-38. PubMed ID: 20446865
[TBL] [Abstract][Full Text] [Related]
16. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines.
Chang TK; Yu L; Maurel P; Waxman DJ
Cancer Res; 1997 May; 57(10):1946-54. PubMed ID: 9157990
[TBL] [Abstract][Full Text] [Related]
17. Glufosfamide as a new oxazaphosphorine anticancer agent.
Mazur L; Opydo-Chanek M; Stojak M
Anticancer Drugs; 2011 Jul; 22(6):488-93. PubMed ID: 21427562
[TBL] [Abstract][Full Text] [Related]
18. Aldehyde dehydrogenase activity as the basis for the relative insensitivity of murine pluripotent hematopoietic stem cells to oxazaphosphorines.
Kohn FR; Sladek NE
Biochem Pharmacol; 1985 Oct; 34(19):3465-71. PubMed ID: 2996550
[TBL] [Abstract][Full Text] [Related]
19. Metabolism and pharmacokinetics of oxazaphosphorines.
Boddy AV; Yule SM
Clin Pharmacokinet; 2000 Apr; 38(4):291-304. PubMed ID: 10803453
[TBL] [Abstract][Full Text] [Related]
20. Potentiation of the cytotoxic action of mafosfamide by N-isopropyl-p-formylbenzamide, a metabolite of procarbazine.
Maki PA; Sladek NE
Cancer Res; 1991 Aug; 51(16):4170-5. PubMed ID: 1868438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
